Pharmaceutical compositions of chondroitinase ABC isolated from Proteus vulgaris ATCC 6896
US6001630A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 18, 1995 |
| Grant date | Dec 14, 1999 |
| Priority date | — |
| Expiry date | May 18, 2015 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG03C2001/0471
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A crystallizable, purified chondroitinase ABC having a molecular weight of about 100,000 dalton by the measurement of the SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and the measurement by the gel permeation chromatography method, having alanine as the N-terminal amino acid and proline as the C-terminal amino acid is disclosed. A process for the purification of the crystallizable purified chondroitinase ABC comprising removing nucleic acid from an surfactant solution extract obtained from cells of chondroitinase ABC-producing microorganisms and chromatographically treating by concentration gradient elution using a weak cation exchange resin or a strong cation exchange resin is disclosed. A composition comprising a chondroitinase and serum albumin, gelatin, or a nonionic surfactant is used to treat disc displacement. The enzyme is isolate from Proteus vulgaris ATCC 6896.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.